MedTrace Logo

Dose Regimen Study of SLI-F06 in Healthy Volunteers

NCT05501327 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2023-07-27

No results posted yet for this study

Summary

Multi-center, dose-regimen, double-blind study evaluating the safety and efficacy of 4 doses of SLI-F06 compared with vehicle for improvement in scar appearance

Conditions

  • Scar
  • Wound Healing

Interventions

DRUG

SLI-F06

Skin injection of SLI-F06 at each wound edge after closure of punch biopsy excision.

Sponsors & Collaborators

  • Scarless Laboratories, Inc.

    lead INDUSTRY

Principal Investigators

  • Elisabeth J Leeflang, MD · Scarless Laboratories, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-25
Primary Completion
2024-07-25
Completion
2024-10-25
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05501327 on ClinicalTrials.gov